JP2013505930A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013505930A5 JP2013505930A5 JP2012530402A JP2012530402A JP2013505930A5 JP 2013505930 A5 JP2013505930 A5 JP 2013505930A5 JP 2012530402 A JP2012530402 A JP 2012530402A JP 2012530402 A JP2012530402 A JP 2012530402A JP 2013505930 A5 JP2013505930 A5 JP 2013505930A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- alkenyl
- heteroaryl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 16
- 125000001072 heteroaryl group Chemical group 0.000 claims 15
- 125000003107 substituted aryl group Chemical group 0.000 claims 14
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 10
- -1 substituted Chemical class 0.000 claims 9
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 7
- 125000002252 acyl group Chemical group 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 239000013067 intermediate product Substances 0.000 claims 5
- 125000000547 substituted alkyl group Chemical group 0.000 claims 5
- 125000004103 aminoalkyl group Chemical group 0.000 claims 4
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 2
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- DISVMXDWAMMVLT-UHFFFAOYSA-N 10-benzyl-2-(2-chlorophenyl)-7,8,9,11-tetrahydro-3h-pyrazolo[4,5]pyrido[5,6-a][1,4]diazepine-1,5-dione Chemical compound ClC1=CC=CC=C1N1C(=O)C2=C3CN(CC=4C=CC=CC=4)CCCN3C(=O)C=C2N1 DISVMXDWAMMVLT-UHFFFAOYSA-N 0.000 claims 1
- GDWVEYKRLIYGKX-UHFFFAOYSA-N 10-benzyl-2-(2-methoxyphenyl)-7,8,9,11-tetrahydro-3h-pyrazolo[4,5]pyrido[5,6-a][1,4]diazepine-1,5-dione Chemical compound COC1=CC=CC=C1N1C(=O)C2=C3CN(CC=4C=CC=CC=4)CCCN3C(=O)C=C2N1 GDWVEYKRLIYGKX-UHFFFAOYSA-N 0.000 claims 1
- AQVJNNMDCSWPMV-UHFFFAOYSA-N 2,7-dihydropyrido[1,2-a][1,4]diazepine-1,5-dione Chemical compound C1(C=2N(C(C=CN1)=O)CC=CC=2)=O AQVJNNMDCSWPMV-UHFFFAOYSA-N 0.000 claims 1
- XCEHGPJYDIOHTC-UHFFFAOYSA-N 2-(2-chlorophenyl)-10-(pyridin-2-ylmethyl)-7,8,9,11-tetrahydro-3h-pyrazolo[4,5]pyrido[5,6-a][1,4]diazepine-1,5-dione Chemical compound ClC1=CC=CC=C1N1C(=O)C2=C3CN(CC=4N=CC=CC=4)CCCN3C(=O)C=C2N1 XCEHGPJYDIOHTC-UHFFFAOYSA-N 0.000 claims 1
- PQSVOKDNSZFBAD-UHFFFAOYSA-N 2-(2-chlorophenyl)-10-[(1-methylpyrazol-3-yl)methyl]-7,8,9,11-tetrahydro-3h-pyrazolo[4,5]pyrido[5,6-a][1,4]diazepine-1,5-dione Chemical compound CN1C=CC(CN2CC=3N(C(C=C4C=3C(N(C=3C(=CC=CC=3)Cl)N4)=O)=O)CCC2)=N1 PQSVOKDNSZFBAD-UHFFFAOYSA-N 0.000 claims 1
- IDCYRHQZIMSXNT-UHFFFAOYSA-N 2-(2-chlorophenyl)-10-[(2-chlorophenyl)methyl]-7,8,9,11-tetrahydro-3h-pyrazolo[4,5]pyrido[5,6-a][1,4]diazepine-1,5-dione Chemical compound ClC1=CC=CC=C1CN1CC2=C3C(=O)N(C=4C(=CC=CC=4)Cl)NC3=CC(=O)N2CCC1 IDCYRHQZIMSXNT-UHFFFAOYSA-N 0.000 claims 1
- YTGBUSQTIGZPPO-UHFFFAOYSA-N 2-(2-chlorophenyl)-10-[(2-methoxyphenyl)methyl]-7,8,9,11-tetrahydro-3h-pyrazolo[4,5]pyrido[5,6-a][1,4]diazepine-1,5-dione Chemical compound COC1=CC=CC=C1CN1CC2=C3C(=O)N(C=4C(=CC=CC=4)Cl)NC3=CC(=O)N2CCC1 YTGBUSQTIGZPPO-UHFFFAOYSA-N 0.000 claims 1
- JENINVSFDRKCKM-UHFFFAOYSA-N 2-(2-chlorophenyl)-10-[(3-chlorophenyl)methyl]-7,8,9,11-tetrahydro-3h-pyrazolo[4,5]pyrido[5,6-a][1,4]diazepine-1,5-dione Chemical compound ClC1=CC=CC(CN2CC=3N(C(C=C4C=3C(N(C=3C(=CC=CC=3)Cl)N4)=O)=O)CCC2)=C1 JENINVSFDRKCKM-UHFFFAOYSA-N 0.000 claims 1
- FWOUVVOPMDNLTL-UHFFFAOYSA-N 2-(2-chlorophenyl)-10-[(3-methoxyphenyl)methyl]-7,8,9,11-tetrahydro-3h-pyrazolo[4,5]pyrido[5,6-a][1,4]diazepine-1,5-dione Chemical compound COC1=CC=CC(CN2CC=3N(C(C=C4C=3C(N(C=3C(=CC=CC=3)Cl)N4)=O)=O)CCC2)=C1 FWOUVVOPMDNLTL-UHFFFAOYSA-N 0.000 claims 1
- WMIICUNBBWCKDS-UHFFFAOYSA-N 2-(2-chlorophenyl)-10-[(4-chlorophenyl)methyl]-7,8,9,11-tetrahydro-3h-pyrazolo[4,5]pyrido[5,6-a][1,4]diazepine-1,5-dione Chemical compound C1=CC(Cl)=CC=C1CN1CC2=C3C(=O)N(C=4C(=CC=CC=4)Cl)NC3=CC(=O)N2CCC1 WMIICUNBBWCKDS-UHFFFAOYSA-N 0.000 claims 1
- FCZWOXRJSYVTON-UHFFFAOYSA-N 2-(2-chlorophenyl)-10-[(4-methoxyphenyl)methyl]-7,8,9,11-tetrahydro-3h-pyrazolo[4,5]pyrido[5,6-a][1,4]diazepine-1,5-dione Chemical compound C1=CC(OC)=CC=C1CN1CC2=C3C(=O)N(C=4C(=CC=CC=4)Cl)NC3=CC(=O)N2CCC1 FCZWOXRJSYVTON-UHFFFAOYSA-N 0.000 claims 1
- FQIOOGDMVOLMFS-UHFFFAOYSA-N 2-(2-chlorophenyl)-3,7,8,10-tetrahydropyrazolo[4,5]pyrido[5,6-a][1,4]oxazine-1,5-dione Chemical compound ClC1=CC=CC=C1N1C(=O)C2=C3COCCN3C(=O)C=C2N1 FQIOOGDMVOLMFS-UHFFFAOYSA-N 0.000 claims 1
- GNVGXVJPFSNSKT-UHFFFAOYSA-N 2-(2-chlorophenyl)-3,7,8,9,10,11-hexahydropyrazolo[4,5]pyrido[5,6-a][1,4]diazepine-1,5-dione Chemical compound ClC1=CC=CC=C1N1C(=O)C2=C3CNCCCN3C(=O)C=C2N1 GNVGXVJPFSNSKT-UHFFFAOYSA-N 0.000 claims 1
- JRKSQSWCFISGJK-UHFFFAOYSA-N 2-(2-methoxyphenyl)-10-(pyridin-2-ylmethyl)-7,8,9,11-tetrahydro-3h-pyrazolo[4,5]pyrido[5,6-a][1,4]diazepine-1,5-dione Chemical compound COC1=CC=CC=C1N1C(=O)C2=C3CN(CC=4N=CC=CC=4)CCCN3C(=O)C=C2N1 JRKSQSWCFISGJK-UHFFFAOYSA-N 0.000 claims 1
- DQKCDKBMEPYLJK-UHFFFAOYSA-N 2-(2-methoxyphenyl)-10-[(3-methoxyphenyl)methyl]-7,8,9,11-tetrahydro-3h-pyrazolo[4,5]pyrido[5,6-a][1,4]diazepine-1,5-dione Chemical compound COC1=CC=CC(CN2CC=3N(C(C=C4C=3C(N(C=3C(=CC=CC=3)OC)N4)=O)=O)CCC2)=C1 DQKCDKBMEPYLJK-UHFFFAOYSA-N 0.000 claims 1
- COIMBYVEHYQEMU-UHFFFAOYSA-N 9-benzyl-2-(2-chlorophenyl)-3,7,8,10-tetrahydropyrazolo[4,5]pyrido[5,6-a]pyrazine-1,5-dione Chemical compound ClC1=CC=CC=C1N1C(=O)C2=C3CN(CC=4C=CC=CC=4)CCN3C(=O)C=C2N1 COIMBYVEHYQEMU-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 206010002199 Anaphylactic shock Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims 1
- 102000004316 Oxidoreductases Human genes 0.000 claims 1
- 108090000854 Oxidoreductases Proteins 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 1
- 125000005217 alkenylheteroaryl group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 230000002152 alkylating effect Effects 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 210000005252 bulbus oculi Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000007822 coupling agent Substances 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003027 ear inner Anatomy 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 230000002008 hemorrhagic effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000003959 neuroinflammation Effects 0.000 claims 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- CYMJPJKHCSDSRG-UHFFFAOYSA-N pyrazolidine-3,4-dione Chemical class O=C1CNNC1=O CYMJPJKHCSDSRG-UHFFFAOYSA-N 0.000 claims 1
- 208000017443 reproductive system disease Diseases 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- QAGPTTNFAWOFFR-UHFFFAOYSA-N tert-butyl 2-(2-chlorophenyl)-1,5-dioxo-7,8,9,11-tetrahydro-3h-pyrazolo[4,5]pyrido[5,6-a][1,4]diazepine-10-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCN(C(C=2)=O)C1=C(C1=O)C=2NN1C1=CC=CC=C1Cl QAGPTTNFAWOFFR-UHFFFAOYSA-N 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 0 C*C(*)(C(*)(*)C(C)(C)C(*)(*)*(C)*C1(C)*)N/I1=C(\C(C(C)C(OC)=O)NN1*)/C1=O Chemical compound C*C(*)(C(*)(*)C(C)(C)C(*)(*)*(C)*C1(C)*)N/I1=C(\C(C(C)C(OC)=O)NN1*)/C1=O 0.000 description 8
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09171466.7 | 2009-09-28 | ||
| EP09171466A EP2305679A1 (en) | 2009-09-28 | 2009-09-28 | Pyrazoline dione derivatives as nadph oxidase inhibitors |
| PCT/IB2010/054329 WO2011036651A1 (en) | 2009-09-28 | 2010-09-27 | Pyrazoline dione derivatives as nadph oxidase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013505930A JP2013505930A (ja) | 2013-02-21 |
| JP2013505930A5 true JP2013505930A5 (enExample) | 2013-08-08 |
| JP5707406B2 JP5707406B2 (ja) | 2015-04-30 |
Family
ID=41347804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012530402A Expired - Fee Related JP5707406B2 (ja) | 2009-09-28 | 2010-09-27 | Ｎａｄｐｈオキシダーゼインヒビターとしてのピラゾリンジオン誘導体 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9394306B2 (enExample) |
| EP (2) | EP2305679A1 (enExample) |
| JP (1) | JP5707406B2 (enExample) |
| KR (1) | KR101791273B1 (enExample) |
| CN (1) | CN102686590B (enExample) |
| AU (1) | AU2010299487B2 (enExample) |
| BR (1) | BR112012004208A2 (enExample) |
| CA (1) | CA2770278C (enExample) |
| CY (1) | CY1119780T1 (enExample) |
| DK (1) | DK2483271T3 (enExample) |
| ES (1) | ES2644857T3 (enExample) |
| HR (1) | HRP20171638T1 (enExample) |
| HU (1) | HUE035058T2 (enExample) |
| IL (1) | IL218814A0 (enExample) |
| LT (1) | LT2483271T (enExample) |
| ME (1) | ME03040B (enExample) |
| NO (1) | NO2483271T3 (enExample) |
| PL (1) | PL2483271T3 (enExample) |
| PT (1) | PT2483271T (enExample) |
| RS (1) | RS56542B1 (enExample) |
| RU (1) | RU2569855C2 (enExample) |
| SI (1) | SI2483271T1 (enExample) |
| SM (1) | SMT201700541T1 (enExample) |
| WO (1) | WO2011036651A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2002835A1 (en) | 2007-06-04 | 2008-12-17 | GenKyo Tex | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2165707A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2166009A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
| EP2166010A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2361911A1 (en) | 2010-02-18 | 2011-08-31 | GenKyoTex SA | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors |
| WO2013078261A1 (en) * | 2011-11-22 | 2013-05-30 | The University Of Maryland, Baltimore | Treatment of muscular conditions and muscular dystrophies |
| JP2015509969A (ja) * | 2012-03-16 | 2015-04-02 | グルソックス・バイオテック・アーベー | Ｎｏｘ４阻害活性を示すチオフェン−ベースの化合物および療法におけるその使用 |
| CA2889029A1 (en) | 2012-10-24 | 2014-05-01 | Glucox Biotech Ab | Triazine derivatives for the treatment of conditions associated with nicotinamide adenine dinucleotide phosphate oxidase |
| EP2857399A1 (en) | 2013-10-03 | 2015-04-08 | GenKyoTex SA | Compounds useful for the treatment of PDE5 inhibitor-poorly responsive erectile dysfunction |
| JP2018505226A (ja) | 2015-02-16 | 2018-02-22 | グルコックス・バイオテック・アーベー | Ｎ２−（３，４−ジメチルフェニル）−６−（（４−（ｐ−トリル）ピペラジン−１−イル）メチル）−１，３，５−トリアジン−２，４−ジアミン |
| EP3098220A1 (en) | 2015-05-28 | 2016-11-30 | GenKyoTex SA | Process for the preparation of a nadph oxidase inhibitor and its polymorphs and uses thereof |
| MY201938A (en) | 2017-08-04 | 2024-03-25 | Skyhawk Therapeutics Inc | Methods and compositions for modulating splicing |
| EP3479843A1 (en) * | 2017-11-01 | 2019-05-08 | GenKyoTex Suisse SA | Use of nox inhibitors for treatment of cancer |
| CN114007613A (zh) | 2019-02-05 | 2022-02-01 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| JP7603595B2 (ja) | 2019-02-06 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| WO2023101418A1 (ko) * | 2021-12-03 | 2023-06-08 | (주)인비보텍 | 난청 또는 이명의 예방 또는 치료용 조성물 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3931407A (en) | 1973-03-01 | 1976-01-06 | American Hoechst Corporation | Method of treatment with and compositions containing condensed pyrroles bearing an N-phenyl substituent |
| DE3728278A1 (de) | 1986-12-17 | 1988-06-23 | Bayer Ag | Herbizide und fungizide mittel auf basis von substituierten pyrazolin-5-on derivaten |
| DE19518082A1 (de) | 1995-05-17 | 1996-11-21 | Merck Patent Gmbh | 4(-Arylaminomethylen)-2,4-dihydropyrazol-3-one |
| US5763496A (en) | 1995-11-27 | 1998-06-09 | The Research Foundation Of State University Of New York | Prevention of atherosclerosis using NADPH oxidase inhibitors |
| TW432073B (en) | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| AU6320998A (en) | 1997-02-21 | 1998-09-09 | Bristol-Myers Squibb Company | Benzoic acid derivatives and related compounds as antiarrhythmic agents |
| IL144468A0 (en) | 2000-07-27 | 2002-05-23 | Pfizer Prod Inc | Use of growth hormone secretagogues for improvement of functional health status |
| WO2002088122A1 (en) | 2001-04-26 | 2002-11-07 | Ajinomoto Co., Inc. | Heterocyclic compounds |
| MXPA04010441A (es) | 2002-04-23 | 2005-02-14 | Shionogi & Co | Derivado de pirazolo[1,5-a]pirimidina e inhibidor de nad(p)h oxidasa que contiene el mismo. |
| AU2004216541A1 (en) | 2003-02-28 | 2004-09-10 | Howard Florey Institute Of Experimental Physiology And Medicine | Therapeutic compositions |
| US20070082910A1 (en) | 2003-04-08 | 2007-04-12 | Mitsubishi Pharma Corporation | Specific nad(p)h oxidase inhibitor |
| WO2005080378A1 (ja) | 2004-02-24 | 2005-09-01 | Mitsubishi Pharma Corporation | 縮合ピリダジン誘導体 |
| RU2266906C1 (ru) * | 2004-04-29 | 2005-12-27 | Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") | Анелированные карбамоилазагетероциклы, способы их получения (варианты), фармацевтическая композиция, фокусированная библиотека |
| WO2007115306A2 (en) | 2006-04-04 | 2007-10-11 | Myriad Genetics, Inc. | Compounds for diseases and disorders |
| KR20070060156A (ko) | 2004-10-04 | 2007-06-12 | 미리어드 제네틱스, 인크. | 알츠하이머병 치료용 화합물 |
| FR2882654B1 (fr) | 2005-03-01 | 2007-04-27 | Servier Lab | Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques |
| US7759337B2 (en) | 2005-03-03 | 2010-07-20 | Amgen Inc. | Phthalazine compounds and methods of use |
| US20070014739A1 (en) | 2005-07-14 | 2007-01-18 | Eldridge Gary R | Compositions and methods for controlling biofilms and bacterial infections |
| DE102005048897A1 (de) | 2005-10-12 | 2007-04-19 | Sanofi-Aventis Deutschland Gmbh | Diacylindazol-derivate als Inhibitoren von Lipasen und Phospholipasen |
| EP2002835A1 (en) * | 2007-06-04 | 2008-12-17 | GenKyo Tex | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2000176A1 (en) | 2007-06-04 | 2008-12-10 | GenKyo Tex | Tetrahydroindole derivatives as NADPH Oxidase inhibitors |
| AR069526A1 (es) | 2007-12-03 | 2010-01-27 | Takeda Pharmaceutical | Compuesto heterociclico que contiene nitrogeno y su uso |
| FR2929276B1 (fr) | 2008-04-01 | 2010-04-23 | Servier Lab | Nouveaux derives de diosmetine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP2166009A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
| EP2165707A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2166008A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2166010A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2361911A1 (en) | 2010-02-18 | 2011-08-31 | GenKyoTex SA | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors |
| EP2361912A1 (en) | 2010-02-18 | 2011-08-31 | GenKyoTex SA | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors |
-
2009
- 2009-09-28 EP EP09171466A patent/EP2305679A1/en not_active Withdrawn
-
2010
- 2010-09-27 WO PCT/IB2010/054329 patent/WO2011036651A1/en not_active Ceased
- 2010-09-27 LT LTEP10782688.5T patent/LT2483271T/lt unknown
- 2010-09-27 NO NO10782688A patent/NO2483271T3/no unknown
- 2010-09-27 AU AU2010299487A patent/AU2010299487B2/en not_active Ceased
- 2010-09-27 HU HUE10782688A patent/HUE035058T2/en unknown
- 2010-09-27 EP EP10782688.5A patent/EP2483271B1/en active Active
- 2010-09-27 ES ES10782688.5T patent/ES2644857T3/es active Active
- 2010-09-27 CA CA2770278A patent/CA2770278C/en not_active Expired - Fee Related
- 2010-09-27 RS RS20171071A patent/RS56542B1/sr unknown
- 2010-09-27 PT PT107826885T patent/PT2483271T/pt unknown
- 2010-09-27 CN CN201080041718.5A patent/CN102686590B/zh not_active Expired - Fee Related
- 2010-09-27 SM SM20170541T patent/SMT201700541T1/it unknown
- 2010-09-27 US US13/394,904 patent/US9394306B2/en not_active Expired - Fee Related
- 2010-09-27 SI SI201031580T patent/SI2483271T1/en unknown
- 2010-09-27 ME MEP-2017-258A patent/ME03040B/me unknown
- 2010-09-27 DK DK10782688.5T patent/DK2483271T3/da active
- 2010-09-27 RU RU2012117796/04A patent/RU2569855C2/ru not_active IP Right Cessation
- 2010-09-27 JP JP2012530402A patent/JP5707406B2/ja not_active Expired - Fee Related
- 2010-09-27 BR BR112012004208A patent/BR112012004208A2/pt not_active Application Discontinuation
- 2010-09-27 KR KR1020127007664A patent/KR101791273B1/ko not_active Expired - Fee Related
- 2010-09-27 HR HRP20171638TT patent/HRP20171638T1/hr unknown
- 2010-09-27 PL PL10782688T patent/PL2483271T3/pl unknown
-
2012
- 2012-03-25 IL IL218814A patent/IL218814A0/en unknown
-
2017
- 2017-11-03 CY CY20171101161T patent/CY1119780T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013505930A5 (enExample) | ||
| AU2019283921B2 (en) | Indole carboxamide compounds useful as kinase inhibitors | |
| AU2016276806B2 (en) | Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same | |
| JP2006520805A5 (enExample) | ||
| RU2012117796A (ru) | Производные пиразолиндиона как ингибиторы надфн-оксидазы | |
| KR102676822B1 (ko) | Atr 키나아제의 헤테로시클릭 저해제 | |
| JP2017527604A (ja) | ｓＧＣ刺激剤 | |
| RU2011116230A (ru) | Пиразолопиридиновые производные как ингибиторы надфн-оксидазы | |
| JP2007505933A5 (enExample) | ||
| US10266491B2 (en) | Carbazole derivatives | |
| JP2020514267A5 (enExample) | ||
| JP2016540017A (ja) | ｓＧＣ刺激物質 | |
| JP2012501312A5 (enExample) | ||
| TW201200518A (en) | Heterocyclic inhibitors of histamine receptors for the treatment of disease | |
| JP2009532452A5 (enExample) | ||
| JP2009529047A5 (enExample) | ||
| WO2011100607A1 (en) | Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as mglur4 allosteric potentiators, compounds, and methods of treating neurological dysfunction | |
| JP2011527684A5 (enExample) | ||
| JP2017527605A (ja) | ｓＧＣ刺激剤 | |
| CA2499134A1 (en) | Fused azole-pyrimidine derivatives | |
| JP2014528479A5 (enExample) | ||
| JP7337067B2 (ja) | ｓＧＣ刺激薬 | |
| JP2008500992A5 (enExample) | ||
| JP2013508382A5 (enExample) | ||
| JP2013542963A5 (enExample) |